Ansell Ltd (ANN) Reports Double-Digit Earnings Growth Across Industrial and Healthcare

Sonal Goyal

17 September 2026 03:40 AM AEST

Ansell Ltd (ANN) Reports Double-Digit Earnings Growth Across Industrial and Healthcare

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Ansell reported FY26 sales of US$2.14 billion, up 6.8% on the prior year, with adjusted sales growth of 5.7% and second-half growth accelerating to 9.2%
Statutory net profit after tax rose to approximately US$208.6 million, while adjusted Earnings Per Share increased 18.5% to US148.6 cents
Both the Industrial and Healthcare divisions reported higher sales and earnings during the year
The company completed US$118.4 million of its US$200 million on-market share buyback in FY26 and plans to continue the program in FY27

Ansell Limited (ASX:ANN) is a Melbourne-based global manufacturer of personal protection and safety solutions, including safety gloves and protective equipment for industrial, healthcare and cleanroom applications. This article reviews the company's FY26 full-year results, its core operations, sector context and developments shareholders are monitoring for FY27.

The share price was AUD 42.16 during the Trading session on 17 September 2026. The stock moved up by 1.25% during the trading session on 17 September 2026.

Company Business

Ansell designs, sources, develops, manufactures, distributes and sells hand and body protection solutions across Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean and North America. The company's operations are organised into Industrial and Healthcare divisions, supplying safety gloves and protective equipment used in manufacturing, construction, laboratory, cleanroom and clinical settings. Ansell reports its financial results in United States dollars, reflecting the global nature of its Revenue base and operations. The company has continued to focus on premium market segments within both its Industrial and Healthcare divisions as part of its strategic positioning.

Sector Context

The personal protective equipment sector is influenced by industrial safety regulations, healthcare procurement standards, and Demand cycles across manufacturing, construction and clinical end markets. Companies in this sector have faced cost pressures from International Trade measures, including tariffs affecting cross-border Supply chains, as well as broader macroeconomic uncertainty affecting industrial demand. Premium product segments, where manufacturers can differentiate on quality, comfort and specialised protection features, have been an area of continued focus for participants in the sector as a means of supporting pricing and margins.

Recent Developments

Ansell released its FY26 full-year results to the ASX on 24 August 2026, for the twelve months ended 30 June 2026. During the year, the company navigated challenging market conditions, including United States tariffs and disruptions linked to conditions in the Middle East, while reporting operational improvements across its business. The company noted that tariff-related costs were fully offset during the year through price increases and productivity gains. Ansell continued its on-market share buyback program during FY26, completing US$118.4 million of a US$200 million program, and indicated the buyback would continue into FY27.

Financial Performance

For FY26, Ansell reported sales of US$2.14 billion, up 6.8% on the prior year, with adjusted sales growth of 5.7% and an acceleration to 9.2% growth in the second half. Statutory net profit after tax rose to approximately US$208.6 million. Adjusted earnings per share increased 18.5% to US148.6 cents, with the company reporting an EBIT Margin of 15% for the year. Both the Industrial and Healthcare divisions reported higher sales and earnings during the period. The company reported record cash generation, with US$752 million in cash and undrawn facilities available, and reduced net Debt to 1.3 times adjusted EBITDA.

Risks to Consider

Ansell's disclosures point to risks including the impact of international trade measures, such as United States tariffs, on input costs and supply chains, and broader macroeconomic uncertainty affecting demand across its industrial and healthcare end markets. Disruptions linked to geopolitical conditions in regions such as the Middle East have also been noted as a Factor affecting the company's operations. Competitive dynamics in both the industrial and healthcare protective equipment markets, currency movements given the company's global revenue base, and execution risk associated with continued margin expansion initiatives are additional considerations.

What to Watch Next

Ansell has provided FY27 guidance targeting adjusted earnings per share of US$1.58 to US$1.70, amid continued macroeconomic uncertainty. The company has indicated it will continue its share buyback program into FY27, alongside ongoing focus on operational excellence and premium segment growth in both its Industrial and Healthcare divisions. The company's half-year results for the six months to 31 December 2026 represent the next scheduled financial disclosure.

Key Insights

Ansell's FY26 results reflect record sales, double-digit adjusted earnings per share growth and margin expansion, achieved despite Tariff and geopolitical headwinds during the year. The company's strengthened balance sheet, reduced Leverage and continued share buyback program support its FY27 targets. Continued focus on premium market segments across both Industrial and Healthcare divisions is likely to remain central to the company's strategy.

FAQs

Q: What does Ansell Limited manufacture?

A:Ansell designs, manufactures and sells hand and body protection solutions, including safety gloves and protective equipment, for industrial, healthcare and cleanroom applications.

Q: What was Ansell's revenue for FY26?

A:Ansell reported sales of US$2.14 billion for FY26, up 6.8% on the prior year, with adjusted sales growth of 5.7%.

Q: What was Ansell's earnings per share for FY26?

A:Adjusted earnings per share for FY26 increased 18.5% to US148.6 cents.

Q: What is Ansell's FY27 guidance?

A:Ansell has provided FY27 guidance targeting adjusted earnings per share of US$1.58 to US$1.70.

Q: Is Ansell continuing its share buyback program?

A:Ansell completed US$118.4 million of a US$200 million on-market share buyback in FY26 and has indicated the program will continue into FY27.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.